OBJECTIVES: The incidence of endometrial cancer has recently increased substantially and studies have shown that altered levels of exogenous and endogenous hormones are associated with individual variation in endometrial cancer risk. The environmental and reproductive risk factors that influence these hormones are well known, however, genetic variants involved in hormone biosynthesis and estrogen metabolism have not been well established in endometrial cancer. METHODS: To determine whether polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways are associated with endometrial cancer risk, 28 polymorphisms in 18 genes were genotyped in 191 endometrial cancer cases and 291 healthy controls. RESULTS: The GSTM1 deletion and the variant (GG) genotype of the CYP1B1 rs1800440 polymorphism were associated with a decreased risk of developing endometrial cancer. Furthermore, combinations of haplotypes in CYP1A1, CYP1B1 and GSTs were associated with a decreased risk. The analysis of the repeat polymorphisms revealed that women with the long repeat allele length of the ESR1 (GT)n repeat polymorphism were at an increased risk of developing endometrial cancer. Conversely, women with two long repeat length alleles of the (CAG)n repeat polymorphism in the AR correlated with a decrease in endometrial cancer risk compared to women with one or two alleles with the short repeat length. CONCLUSIONS: The findings are consistent with our hypothesis that variability in genes involved in steroidogenesis and estrogen metabolism may alter the risk of developing endometrial cancer, suggesting that they may be useful as biomarkers for genetic susceptibility to endometrial cancer. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
OBJECTIVES: The incidence of endometrial cancer has recently increased substantially and studies have shown that altered levels of exogenous and endogenous hormones are associated with individual variation in endometrial cancer risk. The environmental and reproductive risk factors that influence these hormones are well known, however, genetic variants involved in hormone biosynthesis and estrogen metabolism have not been well established in endometrial cancer. METHODS: To determine whether polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways are associated with endometrial cancer risk, 28 polymorphisms in 18 genes were genotyped in 191 endometrial cancer cases and 291 healthy controls. RESULTS: The GSTM1 deletion and the variant (GG) genotype of the CYP1B1rs1800440 polymorphism were associated with a decreased risk of developing endometrial cancer. Furthermore, combinations of haplotypes in CYP1A1, CYP1B1 and GSTs were associated with a decreased risk. The analysis of the repeat polymorphisms revealed that women with the long repeat allele length of the ESR1 (GT)n repeat polymorphism were at an increased risk of developing endometrial cancer. Conversely, women with two long repeat length alleles of the (CAG)n repeat polymorphism in the AR correlated with a decrease in endometrial cancer risk compared to women with one or two alleles with the short repeat length. CONCLUSIONS: The findings are consistent with our hypothesis that variability in genes involved in steroidogenesis and estrogen metabolism may alter the risk of developing endometrial cancer, suggesting that they may be useful as biomarkers for genetic susceptibility to endometrial cancer. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Authors: Xiyan Mu; Xue Du; Kui Yao; Jitong Zhao; Ce Bian; Qiao Wang; Hongwei Ma; Tao Yi; Yang Wu; Xia Zhao Journal: Int J Clin Exp Pathol Date: 2015-06-01
Authors: Stalo Karageorgi; Jennifer Prescott; Jason Y Y Wong; I-Min Lee; Julie E Buring; Immaculata De Vivo Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-05-10 Impact factor: 4.254
Authors: Eva Lundin; Isaac Wirgin; Annekatrin Lukanova; Yelena Afanasyeva; Vittorio Krogh; Tomas Axelsson; Kari Hemminki; Tess V Clendenen; Alan A Arslan; Nina Ohlson; Sabina Sieri; Nirmal Roy; Karen L Koenig; Annika Idahl; Franco Berrino; Paolo Toniolo; Göran Hallmans; Asta Försti; Paola Muti; Per Lenner; Roy E Shore; Anne Zeleniuch-Jacquotte Journal: Cancer Epidemiol Date: 2012-05-25 Impact factor: 2.984
Authors: Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano Journal: Front Pharmacol Date: 2018-09-19 Impact factor: 5.810